NASDAQ$PIII

P3 Health Partners Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Reported strong growth in the third quarter of 2022, driven by the company's healthcare model.

P3 Health Partners reported a strong quarter of growth with a 75% revenue increase year-to-date compared to the prior year period. The company's healthcare model enables collaboration between payors, patients, and providers to improve patient outcomes.

  • Reported strong revenue growth in the third quarter of 2022.
  • The growth demonstrates the power of the healthcare model.
  • COVID-19 is expected to impact future results to a lesser extent than in 2021.
  • Management will host a conference call and webcast to provide a corporate and financial update.

Headline financials

Total Revenue

$248M

Previous: $9.00+2758445155.6%
EPS (adj)

-$0.27

No prior period
Capital Expenditures

-$2.28M

No prior period
Free Cash Flow

-$13.5M

Previous: $4.85M-377.4%
Net Income

-$11.2M

Previous: $4.85M-330.3%
Operating Income

-$60M

Previous: -$670K-8863.1%
Gross Profit

$248M

Previous: $9.00+2758444344.4%
Cash & Equivalents

$34.4M

No prior period
Total Assets

$1.38B

No prior period
Stock-Based Comp

$1.78M

No prior period

Revenue & EPS history

P3 Health · Revenue · Quarterly

$248M

Q3 2022+2,758,445,155.6%vs Q3 2021
Beat estimate in 9 of 13 quarters(69%)
ActualEstimate

Revenue by segment

P3 Health · $386M total across 2 segments · Q1 2026

  • Capitated Revenue
    $379M
  • Other Revenue
    $6.89M

Forward guidance

The Company expects COVID-19 to impact our future results to a lesser extent than our full-year 2021 results, P3 expects to incur additional COVID-19 related costs in full year 2022 given the volume of positive cases and “breakthrough” cases (positive cases in vaccinated patients) present in the Company’s markets.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-3.8%

Avg return

Earnings day

+2.0%

Avg return

5 days after

-15.6%

Avg return

30 days after

37%

7 / 19 earnings

Positive

+11.2%

Q1 2026

Best reaction

-36.8%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+11.2%+194.4%
Q4 2026+0.7%-1.8%-5.4%
Q3 2025+0.4%-12.6%-25.9%
Q2 2025-2.5%+5.4%+23.9%
Q1 2025-0.6%-5.9%-19.5%
Q4 2024-4.5%+1.1%-1.2%
Q3 2024-36.8%-42.2%-46.0%
Q2 2024-2.5%-8.7%-24.1%
Q1 2024+2.6%-11.8%-21.6%
Q4 2023-13.3%-22.4%-56.3%
Q4 2021+3.1%-7.6%-12.2%
Q3 2023-2.1%-8.8%-19.0%
Q2 2023+0.9%-10.8%-5.0%
Q4 2022-5.9%-12.7%+15.5%
Q3 2022-11.8%-19.7%-33.5%
Q1 2022-5.9%+2.1%-16.8%
Q2 2022-4.1%+0.6%-14.0%
Q3 2021+0.1%+0.3%-19.9%
Q2 2021-0.7%-0.2%+0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro